PMC:7309518 / 0-698 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":540,"end":548},"obj":"Body_part"},{"id":"T2","span":{"begin":554,"end":559},"obj":"Body_part"},{"id":"T3","span":{"begin":560,"end":571},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma65132"},{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma82780"}],"text":"Guillain-Barré syndrome: The first documented COVID-19–triggered autoimmune neurologic disease\nMore to come with myositis in the offing\n\nAbstract\nObjective\nTo present the COVID-19–associated GBS, the prototypic viral-triggered autoimmune disease, in the context of other emerging COVID-19–triggered autoimmunities, and discuss potential concerns with ongoing neuroimmunotherapies.\n\nMethods\nEleven GBS cases in four key COVID-19 hotspots are discussed regarding presenting symptoms, response to therapies and cross-reactivity of COVID spike proteins with nerve glycolipids. Emerging cases of COVID-19–triggered autoimmune necrotizing myositis (NAM) and encephalopathies are also reviewed in the cont"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T1","span":{"begin":554,"end":559},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0001021"}],"text":"Guillain-Barré syndrome: The first documented COVID-19–triggered autoimmune neurologic disease\nMore to come with myositis in the offing\n\nAbstract\nObjective\nTo present the COVID-19–associated GBS, the prototypic viral-triggered autoimmune disease, in the context of other emerging COVID-19–triggered autoimmunities, and discuss potential concerns with ongoing neuroimmunotherapies.\n\nMethods\nEleven GBS cases in four key COVID-19 hotspots are discussed regarding presenting symptoms, response to therapies and cross-reactivity of COVID spike proteins with nerve glycolipids. Emerging cases of COVID-19–triggered autoimmune necrotizing myositis (NAM) and encephalopathies are also reviewed in the cont"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T1","span":{"begin":0,"end":23},"obj":"Disease"},{"id":"T2","span":{"begin":46,"end":54},"obj":"Disease"},{"id":"T3","span":{"begin":76,"end":94},"obj":"Disease"},{"id":"T4","span":{"begin":113,"end":121},"obj":"Disease"},{"id":"T6","span":{"begin":171,"end":179},"obj":"Disease"},{"id":"T7","span":{"begin":191,"end":194},"obj":"Disease"},{"id":"T8","span":{"begin":227,"end":245},"obj":"Disease"},{"id":"T9","span":{"begin":280,"end":288},"obj":"Disease"},{"id":"T10","span":{"begin":397,"end":400},"obj":"Disease"},{"id":"T11","span":{"begin":419,"end":427},"obj":"Disease"},{"id":"T12","span":{"begin":591,"end":599},"obj":"Disease"},{"id":"T13","span":{"begin":610,"end":641},"obj":"Disease"},{"id":"T14","span":{"begin":633,"end":641},"obj":"Disease"},{"id":"T16","span":{"begin":643,"end":646},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0005071"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0008054"},{"id":"A5","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0021167"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0007179"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"},{"id":"A11","pred":"mondo_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A12","pred":"mondo_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0016098"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0008054"},{"id":"A15","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0021167"},{"id":"A16","pred":"mondo_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/MONDO_0009722"},{"id":"A17","pred":"mondo_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/MONDO_0016098"}],"text":"Guillain-Barré syndrome: The first documented COVID-19–triggered autoimmune neurologic disease\nMore to come with myositis in the offing\n\nAbstract\nObjective\nTo present the COVID-19–associated GBS, the prototypic viral-triggered autoimmune disease, in the context of other emerging COVID-19–triggered autoimmunities, and discuss potential concerns with ongoing neuroimmunotherapies.\n\nMethods\nEleven GBS cases in four key COVID-19 hotspots are discussed regarding presenting symptoms, response to therapies and cross-reactivity of COVID spike proteins with nerve glycolipids. Emerging cases of COVID-19–triggered autoimmune necrotizing myositis (NAM) and encephalopathies are also reviewed in the cont"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1","span":{"begin":146,"end":155},"obj":"http://purl.obolibrary.org/obo/BFO_0000030"},{"id":"T2","span":{"begin":554,"end":559},"obj":"http://purl.obolibrary.org/obo/UBERON_0001021"}],"text":"Guillain-Barré syndrome: The first documented COVID-19–triggered autoimmune neurologic disease\nMore to come with myositis in the offing\n\nAbstract\nObjective\nTo present the COVID-19–associated GBS, the prototypic viral-triggered autoimmune disease, in the context of other emerging COVID-19–triggered autoimmunities, and discuss potential concerns with ongoing neuroimmunotherapies.\n\nMethods\nEleven GBS cases in four key COVID-19 hotspots are discussed regarding presenting symptoms, response to therapies and cross-reactivity of COVID spike proteins with nerve glycolipids. Emerging cases of COVID-19–triggered autoimmune necrotizing myositis (NAM) and encephalopathies are also reviewed in the cont"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":540,"end":548},"obj":"Chemical"},{"id":"T2","span":{"begin":560,"end":571},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_33563"}],"text":"Guillain-Barré syndrome: The first documented COVID-19–triggered autoimmune neurologic disease\nMore to come with myositis in the offing\n\nAbstract\nObjective\nTo present the COVID-19–associated GBS, the prototypic viral-triggered autoimmune disease, in the context of other emerging COVID-19–triggered autoimmunities, and discuss potential concerns with ongoing neuroimmunotherapies.\n\nMethods\nEleven GBS cases in four key COVID-19 hotspots are discussed regarding presenting symptoms, response to therapies and cross-reactivity of COVID spike proteins with nerve glycolipids. Emerging cases of COVID-19–triggered autoimmune necrotizing myositis (NAM) and encephalopathies are also reviewed in the cont"}

{"project":"LitCovid-PubTator","denotations":[{"id":"2","span":{"begin":46,"end":54},"obj":"Disease"},{"id":"3","span":{"begin":65,"end":94},"obj":"Disease"},{"id":"7","span":{"begin":171,"end":179},"obj":"Disease"},{"id":"8","span":{"begin":227,"end":245},"obj":"Disease"},{"id":"9","span":{"begin":280,"end":288},"obj":"Disease"},{"id":"15","span":{"begin":419,"end":427},"obj":"Disease"},{"id":"16","span":{"begin":528,"end":533},"obj":"Disease"},{"id":"17","span":{"begin":591,"end":599},"obj":"Disease"},{"id":"18","span":{"begin":610,"end":641},"obj":"Disease"},{"id":"19","span":{"begin":652,"end":668},"obj":"Disease"}],"attributes":[{"id":"A2","pred":"tao:has_database_id","subj":"2","obj":"MESH:C000657245"},{"id":"A3","pred":"tao:has_database_id","subj":"3","obj":"MESH:D020274"},{"id":"A7","pred":"tao:has_database_id","subj":"7","obj":"MESH:C000657245"},{"id":"A8","pred":"tao:has_database_id","subj":"8","obj":"MESH:D001327"},{"id":"A9","pred":"tao:has_database_id","subj":"9","obj":"MESH:C000657245"},{"id":"A15","pred":"tao:has_database_id","subj":"15","obj":"MESH:C000657245"},{"id":"A16","pred":"tao:has_database_id","subj":"16","obj":"MESH:C000657245"},{"id":"A17","pred":"tao:has_database_id","subj":"17","obj":"MESH:C000657245"},{"id":"A18","pred":"tao:has_database_id","subj":"18","obj":"MESH:D020721"},{"id":"A19","pred":"tao:has_database_id","subj":"19","obj":"MESH:D001927"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Guillain-Barré syndrome: The first documented COVID-19–triggered autoimmune neurologic disease\nMore to come with myositis in the offing\n\nAbstract\nObjective\nTo present the COVID-19–associated GBS, the prototypic viral-triggered autoimmune disease, in the context of other emerging COVID-19–triggered autoimmunities, and discuss potential concerns with ongoing neuroimmunotherapies.\n\nMethods\nEleven GBS cases in four key COVID-19 hotspots are discussed regarding presenting symptoms, response to therapies and cross-reactivity of COVID spike proteins with nerve glycolipids. Emerging cases of COVID-19–triggered autoimmune necrotizing myositis (NAM) and encephalopathies are also reviewed in the cont"}

{"project":"LitCovid-sentences","denotations":[{"id":"T1","span":{"begin":0,"end":24},"obj":"Sentence"},{"id":"T2","span":{"begin":25,"end":94},"obj":"Sentence"},{"id":"T3","span":{"begin":95,"end":135},"obj":"Sentence"},{"id":"T4","span":{"begin":137,"end":145},"obj":"Sentence"},{"id":"T5","span":{"begin":146,"end":155},"obj":"Sentence"},{"id":"T6","span":{"begin":156,"end":380},"obj":"Sentence"},{"id":"T7","span":{"begin":382,"end":389},"obj":"Sentence"},{"id":"T8","span":{"begin":390,"end":572},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Guillain-Barré syndrome: The first documented COVID-19–triggered autoimmune neurologic disease\nMore to come with myositis in the offing\n\nAbstract\nObjective\nTo present the COVID-19–associated GBS, the prototypic viral-triggered autoimmune disease, in the context of other emerging COVID-19–triggered autoimmunities, and discuss potential concerns with ongoing neuroimmunotherapies.\n\nMethods\nEleven GBS cases in four key COVID-19 hotspots are discussed regarding presenting symptoms, response to therapies and cross-reactivity of COVID spike proteins with nerve glycolipids. Emerging cases of COVID-19–triggered autoimmune necrotizing myositis (NAM) and encephalopathies are also reviewed in the cont"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T1","span":{"begin":113,"end":121},"obj":"Phenotype"},{"id":"T2","span":{"begin":227,"end":245},"obj":"Phenotype"},{"id":"T3","span":{"begin":299,"end":313},"obj":"Phenotype"},{"id":"T4","span":{"begin":633,"end":641},"obj":"Phenotype"},{"id":"T5","span":{"begin":652,"end":668},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0100614"},{"id":"A2","pred":"hp_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/HP_0002960"},{"id":"A3","pred":"hp_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/HP_0002960"},{"id":"A4","pred":"hp_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/HP_0100614"},{"id":"A5","pred":"hp_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/HP_0001298"}],"text":"Guillain-Barré syndrome: The first documented COVID-19–triggered autoimmune neurologic disease\nMore to come with myositis in the offing\n\nAbstract\nObjective\nTo present the COVID-19–associated GBS, the prototypic viral-triggered autoimmune disease, in the context of other emerging COVID-19–triggered autoimmunities, and discuss potential concerns with ongoing neuroimmunotherapies.\n\nMethods\nEleven GBS cases in four key COVID-19 hotspots are discussed regarding presenting symptoms, response to therapies and cross-reactivity of COVID spike proteins with nerve glycolipids. Emerging cases of COVID-19–triggered autoimmune necrotizing myositis (NAM) and encephalopathies are also reviewed in the cont"}